Lung Cancer News

Peter J. Mazzone, MD, MPH, pulmonologist and director of the lung cancer program for the Respiratory Institute at Cleveland Clinic, spoke with Healio about presentations on lung cancer given at the CHEST annual meeting, Oct. 17-20, 2021.

In this video, Peter J. Mazzone, MD, MPH, pulmonologist and director of the lung cancer program in the Respiratory Institute at Cleveland Clinic, discusses his presentation on the role of shared decision-making in early-stage lung cancer.

Chimeric antigen receptor T-cell therapy followed by pembrolizumab appeared safe and feasible for patients with malignant pleural mesothelioma, phase 1 trial results published in Cancer Discovery showed.

Researchers found distinct differences between popular digital voice assistants when they were used for information about cancer screening.

Concurrent chemoradiotherapy use among patients with stage III non-small cell lung cancer increased significantly following publication of the PACIFIC trial, according to a Dutch study published in JTO Clinical and Research Reports.

The addition of canakinumab to pembrolizumab and chemotherapy failed to extend PFS or OS among patients with advanced non-small cell lung cancer, according to topline results of a randomized phase 3 trial.

Early results from the PRECIsE multicenter study showed shape-sensing robotic-assisted bronchoscopy yielded high sensitivity for malignancy for pulmonary nodules and had a favorable safety profile.

The addition of sintilimab to chemotherapy prolonged PFS for patients with pretreated EGFR-mutated nonsquamous non-small cell lung cancer, according to topline data released by the agent’s manufacturer.

The FDA expanded the approval of atezolizumab to include adjuvant treatment of certain patients with non-small cell lung cancer.

Among patients with COPD in South Korea, with an intermediate tuberculosis burden, history of pulmonary TB was associated with an increased risk for developing lung cancer, researchers reported.